SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001493152-22-000211
Filing Date
2022-01-04
Accepted
2022-01-04 06:05:19
Documents
12
Period of Report
2021-12-19
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 37349
  Complete submission text file 0001493152-22-000211.txt   209846

Data Files

Seq Description Document Type Size
2 INLINE XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT prph-20211219.xsd EX-101.SCH 3045
3 INLINE XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT prph-20211219_lab.xml EX-101.LAB 34476
4 INLINE XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT prph-20211219_pre.xml EX-101.PRE 22603
6 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3647
Mailing Address 711 STEWART AVE, SUITE 200 GARDEN CITY NEW YORK NY 11530
Business Address 711 STEWART AVE, SUITE 200 GARDEN CITY NEW YORK NY 11530 (215) 345-0919
ProPhase Labs, Inc. (Filer) CIK: 0000868278 (see all company filings)

IRS No.: 232577138 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-21617 | Film No.: 22503978
SIC: 2834 Pharmaceutical Preparations